Table 1 Basic characteristics of included studies
From: The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis
Study | Year | Country | Sample size/N | mGPS group | Age (year)(%) | Survival analysis | NOS score | Tumor stage | Therapy | Mean Follow-up (month) | Research duration |
|---|---|---|---|---|---|---|---|---|---|---|---|
Partridge et al. [30] | 2012 | UK | 102 (16/20/66) | 0/1/2 | ≤ 72, (50%) | M | 6 | Advanced | Chemotherapy | – | 2006.01–2006.10 |
Jamieson et al. [32] | 2011 | UK | 135 (74/61) | Low/high | ≤ 65, (54%) | M | 6 | T2/T3 | Pancreatectomy | – | 2002–2009 |
Torre et al. [29] | 2012 | Italy | 82 (37/45) | Low/high | – | M | 5 | I/IV | Chemotherapy | 19 | 2003–2009 |
Wang et al. [26] | 2012 | China | 177 (115/62) | Low/high | ≤ 65, (70.1%) | U, M | 6 | II/IV | Chemotherapy | 31.33 | 2006–2010 |
Inoue et al. [25] | 2015 | Japan | 440 (367/49/24) | 0/1/2 | ≤ 65, (40.7%) | U | 7 | I/IV | Chemotherapy | 18.7 | 2008–2012 |
Martin et al. [27] | 2014 | Australia | 124 (46/78) | Low/high | – | U, M | 7 | Locally advanced or metastatic | Chemotherapy | 12 | 2008–2012 |
Mitsunaga et al. [18] | 2016 | Japan | 141 (79/39/23) | 0/1/2 | ≤ 67, (50%) | M | 5 | Advanced | Chemotherapy | – | 2008–2013 |
Imaoka et al. [38] | 2016 | Japan | 807 (620/153/34) | 0/1/2 | < 75, (81.9%) | U | 7 | Locally advanced or metastatic | Chemotherapy | 2001–2013 | |
Wu et al. [8] | 2016 | China | 233 (119/114) | Low/high | < 62, (47.6%) | U, M | 5 | Advanced | Chemotherapy | – | 2011–2014 |
Kawai et al. [17] | 2016 | Japan | 1347 (1121/115/111) | 0/1/2 | – | M | 6 | I/IV | Pancreatectomy | 25.3 | 2001–2012 |
Yamada et al. [33] | 2016 | Japan | 305 (243/62) | Low/high | ≤ 65, (50.1%) | U, M | 5 | I/IV | Chemotherapy | – | 2002–2014 |
Liu et al. [15] | 2017 | China | 386 (131/242/13) | 0/1/2 | ≤ 65, (35.8%) | U | 5 | I/IV | Chemotherapy | 8.7 | 2010–2015 |
Iino et al. [24] | 2017 | Japan | 47 (35/12) | Low/high | – | U, M | 7 | Locally advanced or metastatic | Chemotherapy | – | 2010–2015 |
Xiao et al. [34] | 2017 | China | 66 (39/27) | Low/high | – | U, M | 6 | Advanced | Chemotherapy | – | 2012–2013 |
Fujjiwara et al. [35] | 2018 | Japan | 188 (140/21/27) | 0/1/2 | < 70, (54.3%) | U, M | 8 | I/IV | Pancreatectomy | – | 2000–2015 |
Ikuta et al. [36] | 2019 | Japan | 136 (131/5) | Low/high | ≤ 68, (54.4%) | U | 5 | I/IV | Pancreatectomy | 16.8 | 2005–2017 |
Abe et al. [16] | 2018 | Japan | 329 (282/47) | Low/high | < 65, (43.76%) | U, M | 6 | I/IV | Pancreatectomy | – | 1996–2014 |
Shin et al. [31] | 2018 | South Korea | 1092 (587/353/152) | 0/1/2 | – | M | 6 | I/IV | Chemotherapy | 21.6 | 2000–2016 |
Hwang et al. [28] | 2018 | South Korea | 203 (137/66) | Low/high | ≤ 65, (62.1%) | U, M | 8 | Metastatic or recurrent | Chemotherapy | 21.5 | 2016.01-2016.12 |
Nakagawa et al. [37] | 2019 | Japan | 172 (157/15) | Low/high | < 70, (49.4%) | U, M | 6 | I/IV | Pancreatectomy | – | 2006–2015 |